An Open-Label, Baseline-Controlled Study in Children and Adolescents Aged 6 Months - 17 Years to Assess the Immunogenicity, Reactogenicity and Safety of a Quadrivalent Influenza Vaccine in India
Phase of Trial: Phase III
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs Influenza vaccine quadrivalent Abbott Biologicals (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors Abbott Laboratories
- 05 Nov 2019 Status changed from active, no longer recruiting to completed.
- 05 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 12 Nov 2018 New trial record